scispace - formally typeset
M

Michela Colombo

Researcher at University of Milan

Publications -  49
Citations -  1409

Michela Colombo is an academic researcher from University of Milan. The author has contributed to research in topics: Bone marrow & Notch signaling pathway. The author has an hindex of 18, co-authored 42 publications receiving 1212 citations. Previous affiliations of Michela Colombo include Texas Tech University Health Sciences Center & Medical Research Council.

Papers
More filters
Journal ArticleDOI

Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet

TL;DR: Weight loss through a controlled low-calorie diet improves anthropometric indices in obese PCOS patients, reduces ovarian volume and microfollicle number and can restore ovulatory cycles, allowing spontaneous pregnancy.
Journal ArticleDOI

Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist

TL;DR: GnRH antagonists can be safely administered in gonadotrophin-stimulated IUI cycles without luteal phase supplementation because no deleterious effects of GnRH antagonist administration were noted on luteAL progesterone concentration or on the duration of the luteAl phase.
Journal ArticleDOI

Notch-directed microenvironment reprogramming in myeloma: a single path to multiple outcomes

TL;DR: This review will explore the evidences of Notch deregulation in multiple myeloma, the state of the art of the currently known roles of its signaling in the fatal interaction between multipleMyeloma cells, extracellular matrix and cells in the bone marrow stroma, and recent findings concerning the arguments for or against a therapy addressed to Notch signaling inhibition in the cure of multiple Myeloma.
Journal ArticleDOI

Efficacy of double intrauterine insemination in controlled ovarian hyperstimulation cycles

TL;DR: The data indicate that two IUIs performed 12 hours and 34 hours after hCG administration is the most cost-effective regimen for women undergoing COH cycles with clomiphene citrate and gonadotropins.